This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lapchak, P. A. Articles by Zivin, J. A. Search for Related Content PubMed PubMed Citation Articles by Lapchak, P. A. Articles by Zivin, J. A. Related Collections Acute Cerebral Hemorrhage Embolic stroke Neuroprotectors Thrombolysis Other Stroke Treatment - Medical

(Stroke. 2001;32:147.)
© 2001 American Heart Association, Inc.

Original Contributions

Pharmacological Effects of the Spin Trap Agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke Model

Combination Studies With the Thrombolytic Tissue Plasminogen Activator

Paul A. Lapchak, PhD; Deborah F. Chapman, MSc Justin A. Zivin, MD, PhD

From the Department of Neuroscience, University of California at San Diego, La Jolla.

Correspondence to Dr Paul A. Lapchak, Department of Neuroscience, University of California at San Diego, MTF 316, 9500 Gilman Dr, La Jolla, CA 92093-0624. E-mail plapchak{at}ucsd.edu

Background and Purpose—It has been proposed that spin trap agents such as N-t-butyl-phenylnitrone (PBN) may be useful as neuroprotective agents in the treatment of ischemia and stroke. However, to date, there is little information concerning the effectiveness of spin trap agents when administered in combination with the only Food and Drug Administration–approved pharmacological agent for the treatment of stroke, the thrombolytic tissue plasminogen activator (tPA). Thus, we determined the effects of PBN when administered before tPA on hemorrhage and infarct rate and volume. We also compared the effects of PBN with those of 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO), another spin trap agent that has a different chemical structure and trapping profile, on the incidence of infarcts and hemorrhage.

Methods—One hundred sixty-five male New Zealand White rabbits were embolized by injecting a blood clot into the middle cerebral artery via a catheter. Five minutes after embolization, PBN or TEMPO (100 mg/kg) was infused intravenously. Control rabbits received saline, the vehicle required to solubilize the spin traps. In tPA studies, rabbits were given intravenous tPA starting 60 minutes after embolization. Postmortem analysis included assessment of hemorrhage, infarct size and location, and clot lysis.

Results—In the control group, the hemorrhage rate after a thromboembolic stroke was 24%. The amount of hemorrhage was significantly increased to 77% if the thrombolytic tPA was administered. The rabbits treated with PBN in the absence of tPA had a 91% incidence of hemorrhage compared with 33% for the TEMPO-treated group. In the combination drug–treated groups, the PBN/tPA group had a 44% incidence of hemorrhage, and the TEMPO/tPA group had a 42% incidence of hemorrhage. tPA, PBN/tPA, and TEMPO/tPA were similarly effective at lysing clots (49%, 44%, and 33%, respectively) compared with the 5% rate of lysis in the control group. There was no significant effect of drug combinations on the rate or volume of infarcts.

Conclusions—This study suggests that certain spin trap agents may have deleterious effects when administered after an embolic stroke. However, spin trap agents such as PBN or TEMPO, when administered in combination with tPA, may improve the safety of tPA by reducing the incidence of tPA-induced hemorrhage. Overall, the therapeutic benefit of spin trap agents for the treatment of ischemic stroke requires additional scrutiny before they can be considered "safe" therapeutics.

Key Words: ischemia • neuroprotection • nitrogen radicals • oxygen radicals • reactive oxygen species • reperfusion • tissue plasminogen activator • rabbits

This article has been cited by other articles:

				P. H. Proctor and L. P. Tamborello SAINT-I Worked, But the Neuroprotectant Is Not NXY-059 Stroke, October 1, 2007; 38(10): e109 - e109. [Full Text] [PDF]

				M. Castellanos, R. Leira, J. Serena, M. Blanco, S. Pedraza, J. Castillo, and A. Davalos Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke Stroke, July 1, 2004; 35(7): 1671 - 1676. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, S. Pakola, D. Song, J. Wei, and J. A. Zivin Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits Stroke, September 1, 2002; 33(9): 2279 - 2284. [Abstract] [Full Text] [PDF]

				R. M. Dijkhuizen, M. Asahi, O. Wu, B. R. Rosen, and E. H. Lo Rapid Breakdown of Microvascular Barriers and Subsequent Hemorrhagic Transformation After Delayed Recombinant Tissue Plasminogen Activator Treatment in a Rat Embolic Stroke Model Stroke, August 1, 2002; 33(8): 2100 - 2104. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, D. Song, J. Wei, R. Purdy, and J. A. Zivin Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator Stroke, June 1, 2002; 33(6): 1665 - 1670. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, D. Song, J. Wei, and J. A. Zivin Neuroprotective Effects of the Spin Trap Agent Disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) in a Rabbit Small Clot Embolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator Stroke, May 1, 2002; 33(5): 1411 - 1415. [Abstract] [Full Text] [PDF]

				T. Sumii and E. H. Lo Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats Stroke, March 1, 2002; 33(3): 831 - 836. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, D. Song, and J. A. Zivin The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator-Induced Intracerebral Hemorrhage After Thromboembolic Stroke Stroke, January 1, 2002; 33(1): 147 - 152. [Abstract] [Full Text] [PDF]

				B.-Q. Zhao, Y. Suzuki, K. Kondo, Y. Ikeda, and K. Umemura Combination of a Free Radical Scavenger and Heparin Reduces Cerebral Hemorrhage After Heparin Treatment in a Rabbit Middle Cerebral Artery Occlusion Model Stroke, September 1, 2001; 32(9): 2157 - 2163. [Abstract] [Full Text] [PDF]

				E. Tejima, Y. Katayama, Y. Suzuki, T. Kano, and E. H. Lo Hemorrhagic Transformation After Fibrinolysis With Tissue Plasminogen Activator : Evaluation of Role of Hypertension With Rat Thromboembolic Stroke Model Stroke, June 1, 2001; 32(6): 1336 - 1340. [Abstract] [Full Text] [PDF]